Brief description and aims of work
The company began operations in 1996 with the aim of supplying corporate intelligence products and services to biotechnology industry practitioners. With sales in North America, Europe and Asia, Biovista has a presence in all geographic locations where world‐class biotechnology research and business are conducted. Biovista supplies products for knowledge intensive applications in the healthcare, pharmaceutical and biotechnology industries. Biovista’s technology platform is a literature based discovery suite of applications called Discovery Algorithmics™ (DA).
Biovista’s technical expertise lies in a number of areas including information extraction, advanced database design and predictive modelling based on literature analytics. This last capability allows Biovista to perform drug repurposing, adverse event prediction and off target toxicity prediction offering these as services to the pharmaceutical and biotechnology community. The company uses its technology base to create its own IP portfolio of repurposed drugs and has currently over 20 patent applications with the USPTO.
The main role of Biovista is to use and extend its predictive platform technology to perform a series of experiments. The experiments will utilize Biovista's existing database and the data made available by p-medicine in the context of the clinical trials relevant to p-medicine.